

Please type a sign (+) inside this box ☒ PTO/SB/05 (08-00)

Approved for use through 10/31/2002 OMB 0651-0032  
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	PT086P1
First Inventor	Barash et al.
Title	Signal Transduction Pathway Component Polynucleotides, Polypeptides, Antibodies, and Methods Based Thereon
Express Mail Label No.	

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

## ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

- ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
- ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
- ☒ Specification [Total Pages 475]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 2]
- ☒ Unexecuted Declaration [Total Pages 2]
  - ☐ Newly executed (original or copy)
  - ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)
  - ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- ☒ Application Data Sheet. See 37 CFR 1.76.

- ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - ☒ Computer Readable Form (CRF)
  - Specification Sequence Listing on:
    - ☐ CD-ROM or CD-R (2 copies); or
    - ☒ paper (96 pages)
  - ☒ Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet and document(s))
- ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement/ Form PTO/SB/08  
☐ Copies of Citations
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)  
(should be specifically itemized)
- ☐ Certified copy of Priority Document(s)  
(if foreign priority is claimed)
- ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☒ Continuation-in-Part (CIP) of prior application No. 60/234,997; filed September 25, 2000.  
Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

22195

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

NAME (Print/Type)

Kenley K. Hoover

Registration No (Attorney/Agent)

40,302


SIGNATURE

*Kenley K. Hoover*

Date September 20, 2001

Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box Patent Application, Washington, DC 20231.

09/20/01



# FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

## Complete if Known

Application Number	Unassigned
Filing Date	Herewith (September 20, 2001)
First Named Inventor	Barash et al.
Examiner Name	Unassigned
Group Art Unit	Unassigned
Attorney Docket Number	PT086P1

Total amount of payment **764.00**

## METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to.  
Deposit Account Number **08-3425**  
Deposit Account Name **Human Genome Sciences, Inc.**  
☒ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17  
☐ Applicant claims small entity status See 37 CFR 1.27

2. ☐ Payment Enclosed:  
☐ Check ☐ Credit Card ☐ Money Order ☐ Other\*

## FEE CALCULATION

1. BASIC FILING FEE					
Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	710	201	355	Utility filing fee	710.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	
SUBTOTAL (1)					<b>\$710.00</b>

2. EXTRA CLAIM FEES					
Total Claims		Extra Claims	Fee from below	Fee Paid	
Independent Claims	Multiple Dependent				
23	-20*	3	\$18.00	54.00	
3	-3*	0	\$80.00	0.00	
			\$270.00		

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
103	18	203	9	Claims in excess of 20	
102	80	202	40	Independent claims in excess of 3	
104	270	204	135	Multiple dependent claim, if not paid	
108	80	209	40	** Reissue independent claims over original patent	
110	18	210	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					<b>\$54.00</b>

\* or number previously paid, if greater, For Reissues, see above

## FEE CALCULATION (continued)

3. ADDITIONAL FEES					
Fee Code	Large Entity		Small Entity		Fee Description
	Fee (\$)	Fee Code	Fee (\$)	Fee (\$)	
105	130	205	65		Surcharge - late filing fee or oath
127	50	227	25		Surcharge - late provisional filing fee or cover sheet
139	130	139	130		Non-English specification
147	2,520	147	2,520		For filing a request for <i>ex parte</i> reexamination
112	920*	112	920*		Requesting publication of SIR prior to Examiner action
113	1,840*	113	1,840*		Requesting publication of SIR after Examiner action
115	110	215	55		Extension for reply within first month
116	390	216	195		Extension for reply within second month
117	890	217	445		Extension for reply within third month
118	1,390	218	695		Extension for reply within fourth month
128	1,890	228	945		Extension for reply within fifth month
119	310	219	155		Notice of Appeal
120	310	220	155		Filing a brief in support of an appeal
121	270	221	135		Request for oral hearing
138	1,510	138	1,510		Petition to institute a public use proceeding
140	110	240	55		Petition to revive - unavoidable
141	1,240	241	620		Petition to revive - unintentional
142	1,240	242	620		Utility issue fee (or reissue)
143	440	243	220		Design issue fee
144	600	244	300		Plant issue fee
122	130	122	130		Petitions to the Commissioner
123	50	123	50		Petitions related to provisional applications
126	180	126	180		Submission of Information Disclosure Statement
581	40	481	40		Recording each patent assignment per property (times number of properties)
146	710	246	355		Filing a submission after final rejection (37 CFR 1.129(a))
149	710	249	355		For each additional invention to be examined (37 CFR 1.129(b))
179	710	279	355		Request for Continued Examination (RCE)
169	900	169	900		Request for expedited examination of a design application
Other fee (specify).					
Other fee (specify).					
Other fee (specify).					
SUBTOTAL (3)					<b>\$0.00</b>

\* Reduced by Basic Filing Fee Paid

Submitted By			Complete (if applicable)	
Name (Print/Type)	Kenley K. Hoover	Registration No.:	40,302	Telephone 301-610-5771
Signature:				Date: September 20, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Barash et al.

Attorney Docket No.: PT086P1

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith (September 20, 2001)

Examiner: Unassigned

Title: Signal Transduction Pathway Component Polynucleotides, Polypeptides, Antibodies, and Methods Based Thereon

**STATEMENT UNDER 37 C.F.R. § 1.821(f)**


Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on paper or compact disc) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: September 20, 2001

  
Kenley K. Hoover  
Attorney/Agent for Applicants

Reg. No. 40,302

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: 301-610-5771

Enclosures  
KKH/JS/cmp

095599-092001